Author here. Thanks! I'm pretty sure most of the negative effects of SSRIs were discovered in phase 2 trials, though. Pk trials aren't usually powered to find adverse effects in subpopulations like teenage patients. Same thing with GLP-1 agonists and their effects on addictions (which I think were actually discovered post approval).
That being said, we'd still have to do dose escalation studies for toxicology even if we had great pbpk models. Not denying that.
That being said, we'd still have to do dose escalation studies for toxicology even if we had great pbpk models. Not denying that.